LDH elevation

P2, N=43, Not yet recruiting, AIDS Malignancy Consortium

Phenotypic characterisation was conducted using immunofluorescence staining for molecular markers of plasticity and stemness, and drug resistance was assessed with doxorubicin and enzalutamide, the latter chosen for its emerging relevance in targeting stem-like cancer cell populations. The 3D matrices reproduced the mechanical regulation observed in 2D, providing a physiologically relevant platform for high-throughput investigation of biomechanics-driven cancer progression. These findings highlight the role of matrix stiffness in driving breast cancer phenotypic heterogeneity and support the application of microengineered synthetic matrices for studying metastasis and drug resistance.

Scanning electron microscopy, immunofluorescence, Western Blot, and other molecular functional assays show that the ERRα/LDHA axis drives lactate accumulation, downregulates inflammasome-related proteins (NLRP3, caspase-1, GSDMD and GSDMD-N), thereby suppressing pyroptosis and promoting resistance to cisplatin, carboplatin, and paclitaxel in ovarian cancer cells. Created in BioRender. Ren, Y. (2025) https://BioRender.com/qeh0dw8.

P2, N=39, Recruiting, Ruijin Hospital

In this retrospective cohort, in-hospital mortality after percutaneous cholecystostomy was primarily associated with baseline patient vulnerability and persistent early inflammatory response after the intervention. Radiologic disease burden appeared to correlate with inflammatory recovery rather than mortality. Given the retrospective design, limited number of mortality events, and lack of external validation, these findings should be considered exploratory and hypothesis-generating. Prospective multicenter studies are warranted to further validate these observations.

The MYD88 L265P mutation is associated with poor prognosis in patients with treatment-naive DLBCL, and its VAF can reflect tumor burden. ddPCR technology facilitates the detection of MYD88 L265P mutation, which can be used for serial dynamic monitoring of DLBCL patients to guide efficacy evaluation and predict treatment outcomes.

Ten months after onset, persistent fever, neurological deterioration, hypoxemia, and sustained LDH elevation developed, and IVLBCL was finally diagnosed by a random skin biopsy. This case illustrates the extremely rare phenomenon of the repeated spontaneous remission in IVLBCL.

Therapeutically, as a clinically approved ALDH2 inhibitor, disulfiram exerts its anti-tumor effect by selective reprogramming TAMs metabolism. Overall, our findings delineate a druggable ALDH2-metabolism-epigenetics axis in antitumor immunity, nominating ALDH2 inhibition for combination immunotherapy.

The mutation frequencies of PIM1, MYD88, KMT2D, CD79B, DTX1, and MPEG1 are higher in PB-DLBCL. Patients with mutations in PIM1, MYD88, and DTX1 have a poor prognosis, whereas those with MPEG1 mutations have a favorable prognosis.

This study offers comprehensive insights into the molecular underpinnings of TC progression, highlighting the diagnostic and therapeutic potential of these hub genes and their associated regulatory networks. These findings lay a foundation for developing novel therapeutic strategies targeting these genes in TC management.

Low expression of peripheral blood CD3⁺CD56⁺CD161⁺ NKT cells is associated with increased tumor burden and bortezomib resistance in NDMM, suggesting its potential as a predictive biomarker for treatment response.

Lactate dehydrogenase (LDH) can serve as a potential biomarker for assessing lymphovascular metastasis and prognostic outcomes in endometrial cancer.